DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/6vkbvx/the_u_s_market) has announced the addition of the "The U.S Market Study on Bacterial Conjunctivitis Drugs: Fluoroquinolones to be the Largest Segment by 2024" report to their offering.
The cost of treating bacterial conjunctivitis ranges from USD 377 million to USD 857 million annually in the U.S.
It also quoted that majority of conjunctivitis patients are originally treated by primary care physicians rather than eye care professionals. Around 1% of all primary care office visits in the U.S. are related to conjunctivitis. Bacterial infestation is the second most common cause of infectious conjunctivitis and accounts for 50% to 75% cases among children. This pattern was observed more frequently from December 2012 to April 2013. Thus, potential incidence of bacterial conjunctivitis is one of the major drivers of the bacterial conjunctivitis drugs market in the U.S. However, increasing genericization of antibacterial drugs coupled with upcoming patent expirations,and such few prominent factors are weakening the growth of the market in the near future.
Currently, the market is highly fragmented and competitive due to the involvement of both large and small pharmaceutical companies. Actavis plc (now Allergan plc), Akorn, Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Perrigo Company plc, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., and Valeant Pharmaceuticals International, Inc. are the major players operating in the bacterial conjunctivitis drugs market in the U.S.
During the course of this study it has been observed that majority of the players are focusing on expanding their geographical reach and distribution network through mergers and acquisitions as well as through collaborations with other potential organizations operating in this market.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 U.S. Bacterial Conjunctivitis Drugs Market Overview
Chapter 4 U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class
Chapter 5 U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment
Chapter 6 Recommendations
Chapter 7 Company Profiles
- Actavis plc (now Allergan plc)
- Akorn, Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Novartis AG
- Perrigo Company plc
- Pfizer, Inc.
- Santen Pharmaceutical Co., Ltd.
- Valeant Pharmaceuticals International, Inc.
For more information visit http://www.researchandmarkets.com/research/6vkbvx/the_u_s_market